Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Search
IASLC.org
IASLC Lung Cancer News
Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Home
Authors
Posts by lungcanc
lungcanc
526 POSTS
0 COMMENTS
Charles B. Simone, II, MD
lungcanc
FDA’s New Acting Commissioner
lungcanc
Howard (Jack) West, MD
lungcanc
Lorlatinib’s Role in ROS1-Positive Lung Cancer
lungcanc
PACIFIC Flooded Us with Optimism. Now What?
lungcanc
NCI Director Dr. Norman E. Sharpless Discusses 2019 Budget Plans During...
lungcanc
ICU Care for the Patient with Lung Cancer
lungcanc
Point/Counterpoint: Why TMB Should or Should Not Be Assessed in Patients...
lungcanc
Understanding the Effects of Time to Surgery on Upstaging for Stage...
lungcanc
Financial Incentives and Free Treatment Aids for Smoking Cessation in the...
lungcanc
1
...
16
17
18
...
53
Page 17 of 53
Meeting News
Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation
Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
Load more
Edit with Live CSS
